

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2020/0199227 A1 CHEN et al.

Jun. 25, 2020 (43) **Pub. Date:**

(54) ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOF

(71) Applicant: 23andMe, Inc., Sunnyvale, CA (US)

(72) Inventors: Yu CHEN, Foster City, CA (US); Chingwei Vivian LEE, Foster City, CA (US); Germaine FUH-KELLY, Pacifica, CA (US); Zuoan YI, Mountain View, CA (US); Yao-ming HUANG, San Mateo, CA (US); Valentine YEUNG, Belmont, CA (US); Krista Maureen MCCUTCHEON, Burlingame, CA (US); Samuel NALLE, Pacifica, CA (US); Augusta Eleanor BROUGHTON, Fresno, CA (US); Louise SCHARF, Redwood City, CA (US); Navneet SINGH, San

Foster City, CA (US) (73) Assignee: 23andMe, Inc., Sunnyvale, CA (US)

Francisco, CA (US); Tina THAI, San

Mateo, CA (US); Shouhua XIAO,

(21) Appl. No.: 16/719,108

(22) Filed: Dec. 18, 2019

Related U.S. Application Data

(60) Provisional application No. 62/783,118, filed on Dec. 20, 2018.

Publication Classification

(51) Int. Cl. C07K 16/28 A61P 35/00

(2006.01)(2006.01)

(52) U.S. Cl.

CPC C07K 16/2803 (2013.01); C07K 16/2896 (2013.01); A61P 35/00 (2018.01); C07K 2317/92 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K *2317/33* (2013.01)

(57)**ABSTRACT**

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.

Specification includes a Sequence Listing.